Fluoropyrimidine resistance in colon cancer

Richard Gorlick, Debabrata Banerjee

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

A significant obstacle for the management of patients with colorectal cancer is intrinsic drug resistance or in patients that respond to chemotherapy, acquired drug resistance. Drug resistance can occur through a variety of mechanisms. These include alterations in drug influx, drug efflux, intracellular metabolic activation, intracellular catabolism, through alterations in the drug's target or through numerous changes downstream of the target including alterations in genes involved in the regulation of the cell cycle, apoptosis or in DNA damage repair. In this article, the mechanisms of action and the mechanisms of resistance to the fluoropyrimidines are reviewed focusing on newer studies using tumor samples obtained from patients. Clinical trials that can potentially overcome the relevant mechanisms of resistance are described.

Original languageEnglish (US)
Pages (from-to)409-416
Number of pages8
JournalExpert Review of Anticancer Therapy
Volume2
Issue number4
StatePublished - Aug 2002
Externally publishedYes

Fingerprint

Drug Resistance
Colonic Neoplasms
Pharmaceutical Preparations
DNA Repair
DNA Damage
Colorectal Neoplasms
Cell Cycle
Clinical Trials
Apoptosis
Drug Therapy
Genes
Neoplasms

Keywords

  • 5-fluorouracil
  • Cell cycle
  • Dihydropyrimidine dehydrogenase
  • Drug resistance
  • Fluorodeoxyuridine
  • Methotrexate
  • Thymidine phosphorylase
  • Thymidylate synthase
  • Trinotecan
  • Uridine monophosphate kinase

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research

Cite this

Gorlick, R., & Banerjee, D. (2002). Fluoropyrimidine resistance in colon cancer. Expert Review of Anticancer Therapy, 2(4), 409-416.

Fluoropyrimidine resistance in colon cancer. / Gorlick, Richard; Banerjee, Debabrata.

In: Expert Review of Anticancer Therapy, Vol. 2, No. 4, 08.2002, p. 409-416.

Research output: Contribution to journalArticle

Gorlick, R & Banerjee, D 2002, 'Fluoropyrimidine resistance in colon cancer', Expert Review of Anticancer Therapy, vol. 2, no. 4, pp. 409-416.
Gorlick, Richard ; Banerjee, Debabrata. / Fluoropyrimidine resistance in colon cancer. In: Expert Review of Anticancer Therapy. 2002 ; Vol. 2, No. 4. pp. 409-416.
@article{705d3b3cb76b449dab2052b8c4197d55,
title = "Fluoropyrimidine resistance in colon cancer",
abstract = "A significant obstacle for the management of patients with colorectal cancer is intrinsic drug resistance or in patients that respond to chemotherapy, acquired drug resistance. Drug resistance can occur through a variety of mechanisms. These include alterations in drug influx, drug efflux, intracellular metabolic activation, intracellular catabolism, through alterations in the drug's target or through numerous changes downstream of the target including alterations in genes involved in the regulation of the cell cycle, apoptosis or in DNA damage repair. In this article, the mechanisms of action and the mechanisms of resistance to the fluoropyrimidines are reviewed focusing on newer studies using tumor samples obtained from patients. Clinical trials that can potentially overcome the relevant mechanisms of resistance are described.",
keywords = "5-fluorouracil, Cell cycle, Dihydropyrimidine dehydrogenase, Drug resistance, Fluorodeoxyuridine, Methotrexate, Thymidine phosphorylase, Thymidylate synthase, Trinotecan, Uridine monophosphate kinase",
author = "Richard Gorlick and Debabrata Banerjee",
year = "2002",
month = "8",
language = "English (US)",
volume = "2",
pages = "409--416",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "4",

}

TY - JOUR

T1 - Fluoropyrimidine resistance in colon cancer

AU - Gorlick, Richard

AU - Banerjee, Debabrata

PY - 2002/8

Y1 - 2002/8

N2 - A significant obstacle for the management of patients with colorectal cancer is intrinsic drug resistance or in patients that respond to chemotherapy, acquired drug resistance. Drug resistance can occur through a variety of mechanisms. These include alterations in drug influx, drug efflux, intracellular metabolic activation, intracellular catabolism, through alterations in the drug's target or through numerous changes downstream of the target including alterations in genes involved in the regulation of the cell cycle, apoptosis or in DNA damage repair. In this article, the mechanisms of action and the mechanisms of resistance to the fluoropyrimidines are reviewed focusing on newer studies using tumor samples obtained from patients. Clinical trials that can potentially overcome the relevant mechanisms of resistance are described.

AB - A significant obstacle for the management of patients with colorectal cancer is intrinsic drug resistance or in patients that respond to chemotherapy, acquired drug resistance. Drug resistance can occur through a variety of mechanisms. These include alterations in drug influx, drug efflux, intracellular metabolic activation, intracellular catabolism, through alterations in the drug's target or through numerous changes downstream of the target including alterations in genes involved in the regulation of the cell cycle, apoptosis or in DNA damage repair. In this article, the mechanisms of action and the mechanisms of resistance to the fluoropyrimidines are reviewed focusing on newer studies using tumor samples obtained from patients. Clinical trials that can potentially overcome the relevant mechanisms of resistance are described.

KW - 5-fluorouracil

KW - Cell cycle

KW - Dihydropyrimidine dehydrogenase

KW - Drug resistance

KW - Fluorodeoxyuridine

KW - Methotrexate

KW - Thymidine phosphorylase

KW - Thymidylate synthase

KW - Trinotecan

KW - Uridine monophosphate kinase

UR - http://www.scopus.com/inward/record.url?scp=0036685985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036685985&partnerID=8YFLogxK

M3 - Article

C2 - 12647984

AN - SCOPUS:0036685985

VL - 2

SP - 409

EP - 416

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 4

ER -